Target intelligence / Profile preview

ATP synthase F₀ complex subunit a, mitochondrially encoded (MT-ATP6)

Target
MT-ATP6
Molecular classification
Enzyme (subunit of ATP synthase, a large enzyme complex), Ion channel (forms part of the transmembrane proton channel), Mitochondrial membrane protein
01

Overview

MT-ATP6 is a 226-amino acid, mitochondrially encoded integral membrane protein forming part of the F₀ sector of the ATP synthase complex (complex V) in the mitochondrial inner membrane[1][2]. It is responsible for facilitating proton translocation together with subunit c, forming the core of the mitochondrial proton channel required for ATP production[3][5]. The proton gradient generated by upstream electron transport complexes is utilized by ATP synthase via the rotary mechanism of the F₁ and F₀ domains, converting ADP and phosphate to ATP—the universal energy currency of the cell[1][2][3]. Pathogenic mutations in MT-ATP6 impair ATP generation and are strongly linked to Leigh syndrome and other mitochondrial encephalopathies[4]. Pharmacologic inhibition of ATP synthase F₀ (e.g., by oligomycin) blocks ATP synthesis and can be lethal due to failure of energy conversion in all tissues[1][5][4].

Other names
ATP6ATPASE6MTATP6ATPase-6Su6mF-ATPase protein 6Proton-conducting channelATP synthase membrane subunit 6ATP synthase F₀ complex subunit a
02

Mechanism of action

Inhibition of proton flow (oligomycin, DCCD block the F₀ channel) Impairment of ATP synthesis (energy production blockade) Uncoupling of proton gradient and ATP production

03

Biological functions

Cellular energy generation (ATP synthesis)Oxidative phosphorylationProton translocation (across the mitochondrial inner membrane)Maintenance of mitochondrial membrane potential
04

Disease associations

Mitochondrial disorders (e.g., Leigh syndrome)Neurodegenerative diseaseMyopathyGenetic encephalopathy (NARP syndrome—Neuropathy, Ataxia, and Retinitis Pigmentosa)Metabolic syndromes
05

Safety considerations

High risk of systemic toxicity with pharmacological inhibition due to disruption of cellular energy productionOrgan dysfunction in energetically demanding tissues (brain, muscle, heart) when mutated or inhibitedLethality if completely inhibited (crucial for all eukaryotic cells)
06

Interacting drugs

Oligomycin (natural ATP synthase inhibitor)

2 more in the full profile.

07

Biomarkers

MT-ATP6 mutation analysis for mitochondrial disease/Leigh syndrome riskATP synthase activity measurement in patient fibroblasts

Beyond the preview

Go deeper on ATP synthase F₀ complex subunit a, mitochondrially encoded (MT-ATP6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP synthase F₀ complex subunit a, mitochondrially encoded (MT-ATP6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call